Pure-Play Vanadium Producer's Q3 Revenues Increase 153% YOY
Source: Streetwise Reports  (11/21/17)
With the price of vanadium on the rise, one pure-play producer is reaping the benefits. More >

Home Cooking Fires Four Times More Likely on Thanksgiving, But This 'Undervalued' Company Aims to End That
Source: Streetwise Reports  (11/21/17)
A company that has products that prevent home cooking fires has one analyst calling it an "undervalued and underfollowed play on new safety requirements." More >

Expert's Opinion: 'Back Up the Truck' for this Stock
Source: Ron Struthers for Streetwise Reports  (11/21/17)
Ron Struthers of Struthers' Resource Stock Report takes a look at results from two mining companies, and picks the one he considers a winner.
More >

Cobalt Pure-Play Hitched to Electric Vehicle Boom
Source: Streetwise Reports  (11/21/17)
Forecasts of an electric vehicle boom are behind skyrocketing demand for cobalt, a major component in batteries. In this interview with The Energy Report, Anthony Milewski, CEO of Cobalt 27 Capital Corp., discusses the company's unique position as a two-pronged pure-play on cobalt. More >

Recovering Residential Market Bodes Well for Building Products
Source: Streetwise Reports  (11/21/17)
Russell Stanley, an analyst with Echelon Wealth Partners, provided a review of this hardwood lumber wholesaler. More >

Streamlining of U.S. Environmental Permits Could Benefit Nevada Mine Developer
Source: Streetwise Reports  (11/21/17)
As this company moves closer to bringing a mine into production, a U.S. Department of the Interior decision could help derisk the project. More >

Why the Commodity Supercycle Is Favoring Investors Right Now
Source: Streetwise Reports  (11/21/17)
Precious, base and energy metals are all benefiting from the commodity supercycle, says Louis James, editor of International Speculator, who also discusses his Golden Runway theory of price appreciation and talks about a handful of companies that he believes are on the rise. More >

Analyst's 'Top Pick' Advances Vaccine Candidates
Source: Streetwise Reports  (11/21/17)
Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus. More >

Low-Cost Oil & Gas Player in High-Rent Permian Basin
Source: Streetwise Reports  (11/21/17)
An oil E&P company has acquired rights at low cost in the prolific Permian Basin that it is now exploring and producing. More >

Jack Chan's Weekly Precious Metals Market Update
Source: Jack Chan for Streetwise Reports  (11/20/17)
Technical analyst Jack Chan charts the latest movements in the gold and silver markets.
More >

Oil Charts Showing Extreme Paradoxes
Source: Clive Maund for Streetwise Reports  (11/20/17)
Technical analyst Clive Maund discusses the conflicting signals from oil's price chart and from the COT and Hedgers' charts. More >

Holding on Companies in Gold and Silver, and a Food Multinational
Source: Adrian Day for Streetwise Reports  (11/20/17)
The news from three companies has prompted updates from Adrian Day of Adrian Day Asset Management.
More >

Stock Price Jump Reflects Biotech's Active October
Source: Streetwise Reports  (11/20/17)
This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment.
More >

Maxim's Target Price on Biotech Makes It More Than a Tenbagger
Source: Streetwise Reports  (11/20/17)
Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets.
More >

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate
Source: Streetwise Reports  (11/20/17)
André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer.
More >

Gold in Contradictory Position
Source: Clive Maund for Streetwise Reports  (11/19/17)
The signals for gold are mixed, says technical analyst Clive Maund, who delves into the ramifications. More >

Technical Analyst Sees Weakness in Silver
Source: Clive Maund for Streetwise Reports  (11/19/17)
Technical analyst Clive Maund charts silver and finds the signals contradictory. More >

'Explorer of the Year' Recipient Convincingly Updates Resource in a Booming Zinc Market
Source: The Critical Investor for Streetwise Reports  (11/17/17)
The Critical Investor profiles a company exploring a high-grade zinc property, and explains why he believes the upcoming PEA could surprise markets. More >

AgriTech Company Sells to Organic and Cannabis Markets
Source: Streetwise Reports  (11/16/17)
The company's soon-to-be-announced prefeasibility study will evaluate expansion plans. More >

Could Your Car Be Hacked? This Micro-Cap May Have the Solution
Source: Michael Sheikh for Streetwise Reports  (11/16/17)
The many computer connections in cars make them vulnerable to hacking, says Michael Sheikh, founder of Falcon Strategic Research, who profiles a small company whose software takes a radically different approach to cybersecurity. More >

Three Resource Companies; One Good Buy
Source: Adrian Day for Streetwise Reports  (11/16/17)
Adrian Day of Adrian Day Asset Management reviews the current news and prospects at three resource companies, and comes up with at least one good buy.
More >

Streaming Company's 'Attractive Valuation' Is Behind Analyst's Outperform Rating
Source: Streetwise Reports  (11/16/17)
BMO Capital Markets reviewed this company's Q3/17 financial results and an impending deadline pertaining to one of its streams. More >

Biotech's Target Price Increased as Shares 'Deeply Undervalued'
Source: Streetwise Reports  (11/15/17)
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer.
More >

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing
Source: John McCamant for Streetwise Reports  (11/15/17)
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.
More >

The Holiday Season Comes Early After an Updated PEA Brings In a Bundle Full of Buy Ratings for Precious Metals Explorer
Source: Streetwise Reports  (11/14/17)
Five analysts explain why "several significant improvements" led to their Buy recommendations and highlight what investors need to know. More >